CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Hallmarks of Cancer: Sustaining Proliferative Signaling

Read More
All Posts

Cancer cells stimulate their own growth, which means they become self-sufficient in growth signals and no longer depend on external signals (like Epidermal Growth Factor EGF/ EGFR). Proliferation depends highly on these three important pathways: Akt, MAPK/Erk, and MTOR.

Hallmarks Cancer Sustaining Proliferative SignalingAkt, also known as Protein Kinase B (PKB), represents a family of serine/threonine protein kinases, Akt1, Akt2, and Akt3. Akt1 (v-Akt) was originally discovered as a proto-oncogene and plays a critical role in regulating diverse cellular functions, which include metabolism, growth, proliferation, survival, transcription, and protein synthesis. Akt is activated by various extracellular and intracellular signals, most involving the lipid kinase phosphoinositide 3-kinase (PI3K). It is also a major regulator of cell survival by inhibiting the apoptotic effects of signaling pathways and proteins (like FoxO1).

Mitogen-activated protein kinases (MAPKs) are the central component in numerous signaling cascades that transmit growth, proliferation, and survival signals from the cell surface to the nucleus. Stimulation of receptor-tyrosine kinases (RTKs) by growth factors, engagement of integrins, or changes in cellular homeostasis (stress, etc.) promote the activation of signaling pathways involving Erk (extracellular regulated kinase), p38 MAPK, or Jnk (c-Jun N-terminal kinase). Each of these kinases, in turn, promotes activation of transcription factors such as c-Jun, Ets, Alk, and ATF resulting in cellular growth, survival, repair, and proliferation.

mTOR (mammalian target of rapamycin) is a protein kinase that functions as an ATP and amino acid sensor to balance nutrient and energy availability with cellular growth. mTOR can also be activated or inhibited by other signaling pathways involving Akt, Erk, and AMPK. mTOR in turn regulates a series of metabolic enzymes and other protein kinases that modulate lipid metabolism and biogenesis cellular growth and proliferation, and autophagy.

Learn more about the pathways and proteins involved in Sustaining Proliferative Signaling:

Check out the complete guide to the Hallmarks of Cancer Research targets. Download the eBook Now.

The Hallmarks of Cancer are seminal manuscripts by Doctors Robert Weinberg and Douglas Hanahan and were published in Cell1. The authors proposed the idea that the complexity of cancer can be broken down into smaller subsets of underlying principles. The information here pertains to one Hallmark of Cancer, known as "Sustaining Proliferative Signaling." Other entries in this series explore the other proposed Hallmarks.

Read the additional blog posts in the Hallmarks of Cancer series to learn more:

References:

  1. Hanahan D, Weinberg RA. The hallmarks of cancerCell. 2000;100(1):57-70. doi:10.1016/s0092-8674(00)81683-9
  2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generationCell. 2011;144(5):646-674. doi:10.1016/j.cell.2011.02.013

    18-CEL-47850

Chris Sumner
Chris Sumner
Chris Sumner was the Editor-in-Chief of Lab Expectations. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Recent Posts

Microglial Activation Antibody Toolkit: High-Content Methods to Study TREM2 Signaling

Selecting antibodies for molecular signaling research in neurodegeneration is a complex and nuanced proce...
Ginny Bain, PhD Dec 11, 2024

Cell Preparation Tips for Accurate Flow Cytometry Data

Generating accurate flow cytometry data requires more than just specific and sensitive antibodies validat...
Andrea Tu, PhD Nov 20, 2024

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024